Deep Value: cash covers about 93% of the stock price

This company holds roughly $6M in cash and investments — about 93% of its entire stock-market value, based on its latest quarterly filing. You're paying very little for the actual business. Sometimes that's a genuine bargain or a takeover target, sometimes it's cheap for a reason. Not a buy signal on its own — always ask why it's this cheap.

Cardio Diagnostics Holdings

CDIO

Biotechnology · Healthcare

Price

$2.03

-0.18 (-8.14%)

Market Cap

$6.0M

Exchange

NASDAQ Capital Market

Winston Score

Winston is serious

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Mixed

Growth

Mixed

Cash Flow

Weak

Stability

Good

Valuation

Data not available

Track this stock — start free trial

Share count rising — dilution

+452.2% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 317K (2021) → 1.8M (2025)

Winston Score History

The full picture

Cardio Diagnostics Holdings is a small biotechnology company focused on using artificial intelligence and genetic testing to detect heart disease earlier than traditional methods. Its main product is a blood-based epigenetic test that looks at DNA patterns to assess a person's risk of cardiovascular conditions like heart attacks. The company targets patients, doctors, and health systems looking for more precise ways to identify heart disease risk before symptoms appear.

The company earns revenue by selling its diagnostic tests, though it currently generates very little revenue and spends far more than it brings in — reflected in deeply negative margins. It operates primarily in the United States and is a micro-cap company with a very small commercial footprint. The biggest risk facing Cardio Diagnostics is achieving meaningful commercial adoption and scaling revenue fast enough to avoid running out of cash, as the company depends heavily on continued financing to fund its operations.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-28.3% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+47.4% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$641,212/ year

↑ Rising (+181% vs prior year)

>1,000% of revenue

240.3x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

6.8%ownership

Insiders own a meaningful stake in the company

Cash Runway

~12 months

$6M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Adequate runway but may need to raise capital within 2 years

Heavy R&D investment

Cardio Diagnostics Holdings is putting 4325% of revenue into R&D and that number is rising. That's 240.3x the sector average.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

100.0%

Premium pricing power — 100.0% gross margin

Profit after running costs

Operating Margin

-27950.5%

Losing money on operations — -27950.5%

Return on the money invested

ROCE

-83.6%

Weak — -83.6% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-25.9%

Shrinking sales (-25.9% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-40425.3%

Burning cash (-40425.3%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.04

Conservative — low debt load (0.04)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial